PMID: 718156Oct 1, 1978

Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538

Antimicrobial Agents and Chemotherapy
E J GoldsteinS M Finegold

Abstract

The susceptibilities of 284 anaerobic bacteria, including 55 strains of the Bacteroides fragilis group, were determined by an agar dilution technique to metronidazole and two newer nitroimidazoles, ornidazole and SC-28538. All three agents showed marked in vitro activity against virtually all anaerobic bacteria tested. At concentrations </=1 mug/ml, SC-28538 was significantly more active than either metronidazole or ornidazole. At concentrations of >1 mug/ml, the activities of all three agents were comparable. Propionibacterium and Actinomyces showed significant resistance to all three agents. Anaerobic and microaerophilic members of the genus Streptococcus were also often resistant, in contrast to Peptococcus and Peptostreptococcus strains. In addition, the bactericidal activities of ornidazole and SC-28538 were determined against 27 strains of the B. fragilis group by a broth dilution technique. The minimal inhibitory and minimal bactericidal concentrations of each agent were very close. At concentrations of </=0.5 mug/ml, SC-28538 showed greater bactericidal activity; at concentrations of >/=2 mug/ml, the activies of both agents were similar.

References

Feb 1, 1977·The British Journal of Venereal Diseases·M SköldL Hillström
Dec 1, 1977·Journal of Medicinal Chemistry·R C TweitS Ziecina
Oct 1, 1976·Antimicrobial Agents and Chemotherapy·V L Sutter, S M Finegold
Jun 1, 1975·The Journal of Antimicrobial Chemotherapy·H R InghamP R Uldall
Oct 1, 1973·Journal of Medicinal Chemistry·R C TweitR D Muir
Jul 1, 1972·The Journal of Infectious Diseases·L J Nastro, S M Finegold

Citations

Oct 1, 1996·European Journal of Nuclear Medicine·R S LiuS H Yeh
Apr 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·A BarrowC M Walls
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·R D Rolfe, S M Finegold
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·R D Rolfe, S M Finegold
Jun 1, 1984·Antimicrobial Agents and Chemotherapy·L DubreuilC Romond
Oct 5, 2010·Colloids and Surfaces. B, Biointerfaces·Baljit Singh, Nisha Sharma
Oct 1, 1982·International Journal of Radiation Oncology, Biology, Physics·S Okkan, R Uzel
Apr 11, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jiangbo DuDafang Zhong
Jan 31, 2021·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Brandon A SherrodWilliam T Couldwell

Related Concepts

Anaerobiosis
Bayer 5360
Fungus Drug Sensitivity Tests
Nitroimidazoles
Tiberal

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Actinomycosis

Actinomycosis is a rare, chronic, and slowly progressive granulomatous disease caused by filamentous Gram positive anaerobic bacteria from the Actinomycetaceae family (genus Actinomyces). The disease is characterised by the formation of painful abscesses in the mouth, lungs,breast or gastrointestinal tract. Discover the latest research on actinomycosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.